Clinical Trials

Obesity in patients who have had a heart attack or stroke

Posted on 12/30/2018
Research has shown that treatment with semaglutide (an FDA approved drug) may reduce the risk of stroke and heart attack in people with type 2 diabetes.  The purpose of this study is to assess whether semaglutide reduces the risk of heart attack and stroke in people who are overweight or obese.

You may qualify to participate in this study if:
  • You have had a stroke or heart attack, or have poor circulation (peripheral arterial disease)
  • You are 45 years of age or older
  • You are overweight or obese
  • You are able to attend regular clinic visits and receive phone calls over a period of 3-5 years

If you qualify for this study, you will receive study-related care, including regular health check-ups and guidance on healthy lifestyle choices.  You will also be compensated $50 for every clinic visit you attend up to $1,250.  
What Our Research Patients are Saying
"Last January I had to begin taking insulin for my diabetes. It was life changing for me. I had always been afraid of starting insulin. However, when I qualified for the diabetes clinical trial, it helped me accept this change in my life. The Research Coordinators are the very best you could ask for. They explained everything and let me know what to expect. I could never have controlled my diabetes if it hadn't been for this research program, the research staff and the study doctor. I would recommend participating in a research trial to anyone who has diabetes. It and the research staff are a godsend."
~ C.D

Contact Form


  
DCOL of Longview